-
Safety and efficacy of encorafenib, binimetinib, and cetuximab for BRAFV600E-mutant metastatic colorectal cancer: Results of the Japanese expanded access program Clin. Colorectal Cancer (IF 3.4) Pub Date : 2024-03-09 Daisuke Kotani, Atsuo Takashima, Takeshi Kato, Taroh Satoh, Toshiki Masuishi, Yoshito Komatsu, Manabu Shiozawa, Taito Esaki, Naoki Izawa, Shinji Takeuchi, Hideaki Bando, Satoru Iwasa, Hiroko Hasegawa, Toshifumi Yamaguchi, Hiroya Taniguchi, Yasunori Ushida, Toshiya Oizaki, Chiaki Inoue, Takayuki Yoshino
The phase 3 BEACON CRC study demonstrated the survival benefits of encorafenib and cetuximab, with or without binimetinib (the BEACON triplet or doublet regimen), for -mutant metastatic colorectal cancer (mCRC). This expanded access program (EAP) and subsequent follow-up study assessed the efficacy and safety of the BEACON triplet regimen in Japanese patients with -mutant mCRC. The EAP was an open-label
-
Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review Clin. Colorectal Cancer (IF 3.4) Pub Date : 2024-02-21 Dorien Geusens, Daan Dierickx, Saskia Carton, Eric Van Cutsem, Jeroen Dekervel
Immune checkpoint inhibitors (ICI) are becoming increasingly important in the treatment of (colorectal) cancer. Haemophagocytic lymphohistiocytosis (HLH), which involves an immune hyperactivation, is a rare but life-threatening adverse event of immunotherapy and is difficult to diagnose.
-
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer Clin. Colorectal Cancer (IF 3.4) Pub Date : 2024-02-16 Laura Roazzi, Giorgio Patelli, Katia Bruna Bencardino, Alessio Amatu, Erica Bonazzina, Federica Tosi, Brunella Amoruso, Anna Bombelli, Sara Mariano, Stefano Stabile, Camillo Porta, Salvatore Siena, Andrea Sartore-Bianchi
Liquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular landscape of metastatic colorectal cancer (mCRC) is substantially heterogeneous and dynamic over space and time, ctDNA holds significant advantages as a biomarker for this disease. Numerous studies
-
Consideration of Metastasis-Directed Therapy for Patients with Metastatic Colorectal Cancer: Expert Survey and Systematic Review Clin. Colorectal Cancer (IF 3.4) Pub Date : 2024-01-30 Eric D. Miller, Brett G. Klamer, Jordan M. Cloyd, Timothy M. Pawlik, Terence M. Williams, Kathryn E. Hitchcock, Paul B. Romesser, Harvey J. Mamon, Kimmie Ng, Sepideh Gholami, George J. Chang, Christopher J. Anker
Background A survey of medical oncologists (MOs), radiation oncologists (ROs), and surgical oncologists (SOs) who are experts in the management of patients with metastatic colorectal cancer (mCRC) was conducted to identify factors used to consider metastasis-directed therapy (MDT). Materials and Methods An online survey to assess clinical factors when weighing MDT in patients with mCRC was developed
-
Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study Clin. Colorectal Cancer (IF 3.4) Pub Date : 2024-01-18 Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi, Hideaki Bando, Manabu Shiozawa, Tomohiro Nishina, Hisateru Yasui, Akiyoshi Kanazawa, Koji Ando, Yosuke Horita, Masahiro Goto, Naohiro Okano, Toshikazu Moriwaki, Taroh Satoh, Akihito Tsuji, Kaname Yamashita, Chiharu Asano, Yukiko Abe, Shogo Nomura, Takayuki Yoshino
Background The significance of angiogenic factors as predictors of second-line (2L) chemotherapy efficacy when combined with angiogenesis inhibitors for metastatic colorectal cancer (mCRC) remains unestablished. Patients and Methods In this multicenter prospective observational study, 17 angiogenic factors were analyzed in plasma samples collected at pretreatment and progression stages using a Luminex®
-
Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series Clin. Colorectal Cancer (IF 3.4) Pub Date : 2024-01-18 Tao Pan, Hui Yang, Wu-yi Wang, Yuan-yi Rui, Zi-jian Deng, Yung-chang Chen, Chao Liu, Hai Hu
Although ipilimumab plus nivolumab have significantly improved the survival of metastatic colorectal cancer (CRC) with mismatch repair deficient (dMMR) /microsatellite instability-high (MSI-H), the data on neoadjuvant setting is limited. We enrolled 11 patients with advanced dMMR/MSI-H CRC. 10 patients were locally advanced and 1 was metastatic. Ten patients were treated with 1 dose of ipilimumab (1
-
Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence Clin. Colorectal Cancer (IF 3.4) Pub Date : 2024-01-11 Oliver Piercey, Hui-Li Wong, Clara Leung, Yat Hang To, Valerie Heong, Margaret Lee, Jeanne Tie, Malcolm Steel, Justin M. Yeung, Jacob McCormick, Peter Gibbs, Rachel Wong
A substantial proportion of patients with stage III colorectal cancer (CRC) are older than 70 years. Optimal adjuvant chemotherapy (AC) for older patients (OP) continues to be debated, with subgroup analyses of randomized trials not demonstrating a survival benefit from the addition of oxaliplatin to a fluoropyrimidine backbone. We analyzed the multisite Australian ACCORD registry, which prospectively
-
Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-12-16 Kevin Mok, Claudia Wu, Stephen Chan, Grace Wong, Vincent Wai-Sun Wong, Brigette Ma, Rashid Lui
Immune checkpoint inhibitors have transformed the treatment paradigm for various types of cancer. Nonetheless, with the utilization of these groundbreaking treatments, immune-related adverse events (irAEs) are increasingly encountered. Colonic and hepatic involvement are among the most frequently encountered irAEs. Drug-induced side effects, infectious causes, and tumor-related symptoms are the key
-
Salvage Treatment of Recurrent or Persistent Anal Squamous Cell Carcinoma: The Role of Multi-modality Therapy Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-12-13 Ethan P. Damron, Jordan McDonald, Michael K. Rooney, Prajnan Das, Ethan B. Ludmir, Bruce D. Minsky, Craig Messick, George J. Chang, Van K. Morris, Emma B. Holliday
The standard treatment for recurrent or persistent anal squamous cell carcinoma is surgical salvage, but disease control and survival are suboptimal. Patients treated for recurrent or persistent anal squamous cell carcinoma at our institution from 2002 to 2022 were included. Patients were classified by type of salvage treatment received: surgery alone vs. reirradiation followed by surgery and by whether
-
Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-12-10 Bruno Medonça Protásio, Tiago Biachi de Castria, Renato Natalino, Flávia R. Mangone, Daniel Fernandes Saragiotto, Jorge Sabbaga, Paulo M. Hoff, Roger Chammas
Primary tumor sidedness (PTS) is an independent prognostic factor in patients with metastatic colorectal cancer (CRC), with a worse prognosis for right-sided tumors. There are limited data on the prognostic impact of PTS in stage III CRC. The main objective of this study was to analyze the prognostic impact of PTS in stage III CRC. A retrospective and uni-institutional cohort study was performed in
-
-
-
A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-11-27 Farshid Dayyani, Jasmine Balangue, Jennifer Valerin, Matthew J. Keating, Jason A. Zell, Thomas H. Taylor, May T. Cho
This study determined the safety and recommended phase 2 dose (RP2D) of the multikinase inhibitor cabozantinib in combination with trifluridine/tipiracil (FTD/TPI) in refractory metastatic colorectal carcinoma (mCRC). Single institution investigator-initiated phase 1 study using 3+3 design. Eligible mCRC patients had received prior standard regimens. Cabozantinib was given orally (p.o.) at 20 mg (dose
-
Efficacy of Pyrotinib With/Without Trastuzumab in Treatment-Refractory, HER2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-11-19 Haojie Zhou, Minzhi Lv, Wei Li, Yan Wang, Jing Wu, Qing Liu, Tianshu Liu, Yuehong Cui, Qian Li
Human epidermal growth factor receptor 2 (HER2) is a promising therapeutic target in metastatic colorectal cancer (mCRC). This study was to evaluate the efficacy and safety of pyrotinib alone or pyrotinib with trastuzumab in patients with HER2-positive mCRC. In this prospective observational study, patients with HER2 positive, Ras Sarcoma Viral Oncogene Homolog (RAS) wild type mCRC who received at
-
Real-World Safety and Effectiveness of a Bevacizumab Biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-10-28 Winson Y. Cheung, Setareh Samimi, Kim Ma, Gregory John Knight, Shaqil Kassam, Bruce Colwell, Annie Beaudoin, Mark David Vincent, Mateya Trinkaus, Alain Filion, Katerine Marquis, Hatim Karachiwala, Timothy Asmis, Lucas Sideris, Rajvi J. Wani, Elaine Ngan, Naila Inam, Yinhao Du, Leyla Nunez, Maria Eberg, Mistre Alemayehu, Pierre-Francois Meyer, Johanna Mancini, Carlye Cirone Morris
ABP 215 is a biosimilar to the reference product, bevacizumab, and was one of the first biosimilars approved by Health Canada for the first-line treatment of metastatic colorectal cancer (mCRC). This study aimed to address gaps in real-world evidence (RWE) including patient characteristics, treatment safety (primary objective), and effectiveness (secondary objective) for first-line ABP 215 therapy
-
Propensity-Score Matched Analysis of Survival Outcomes of Adjuvant Therapy in Stage II-III Signet-Ring Cell Carcinoma of the Colon Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-10-26 Sameh Hany Emile, Nir Horesh, Zoe Garoufalia, Rachel Gefen, Victor Strassmann, Steven D. Wexner
Colonic signet ring cell carcinoma (SRCC) is a mucinous adenocarcinoma subtype often associated with poor prognosis. This study assessed the survival benefits of adjuvant therapy after curative resection of stage II-III colonic SRCC. This was a retrospective analysis of outcomes of adjuvant therapy in colonic SRCC using National Cancer Database (2010-2019) data. Patients who received adjuvant therapy
-
Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-10-14 Jacopo Giuliani, Beatrice Mantoan, Daniela Mangiola, Marco Muraro, Giuseppe Napoli, Marina Tommasi, Francesco Fiorica, Marta Mandarà
Abstract not available
-
Optimizing Fecal Occult Blood Test (FOBT) Colorectal Cancer Screening Using Gut Bacteriome as a Biomarker Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-10-13 Moumita Roy Chowdhury, Karina Gisèle Mac Si Hone, Karine Prévost, Philippe Balthazar, Mariano Avino, Mélina Arguin, Jude Beaudoin, Mandy Malick, Michael Desgagné, Gabriel Robert, Michelle Scott, Jean Dubé, Isabelle Laforest-Lapointe, Eric Massé
Colorectal cancer (CRC) is a major cause of cancer mortality in the world. One of the most widely used screening tests for CRC is the immunochemical fecal occult blood test (iFOBT), which detects human hemoglobin from patient's stool sample. Although it is highly efficient in detecting blood from patients with gastro-intestinal lesions, such as polyps and cancers, the iFOBT has a high rate of false
-
Life After Colorectal Cancer: Survivorship the Road Less Traveled Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-10-10 Mehmet Sitki Copur
Abstract not available
-
Management of Older Adults With Colorectal Cancer: The Role of Geriatric Assessment Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-10-08 Ahmet Anil Ozluk, Darryl Outlaw, Mehmet Akce, Mackenzie E. Fowler, Daniel L. Hess, Smith Giri, Grant R. Williams
Older adults share a growing burden of cancer morbidity and mortality. This is present across the spectrum of oncologic diagnoses and is particularly true with colorectal cancer (CRC), where older adults continue to share the burden of diagnoses. However, optimal cancer treatment decision making in older adults remains a significant challenge, as the majority of previous clinical trials shaping the
-
Effectiveness of Biologic Agents Among Hispanic Patients With Metastatic Colorectal Cancer Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-10-06 Riya Patel, Abdissa Negassa, Seda S. Tolu, Ana Acuna-Villaorduna, Sanjay Goel
Randomized clinical trials have defined the survival advantage with the addition of biologic drugs to chemotherapy in patients with metastatic colorectal cancer (mCRC). Under representation of Hispanics contributes to poorly defined outcomes in this group. We aim to determine whether the real-world benefit of biologics extends to Hispanics using a comparative effectiveness research approach. This retrospective
-
Secondary Primary Cancer Risk After Radiation Therapy in Rectal Cancer: A Population-Based Cohort Study With Propensity Score Matching Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-09-19 Anne Schlesinger-Raab, Gabriele Schubert-Fritschle, Mia Kim, Jens Werner, Claus Belka, Hendrik Wolff, Ayman Agha, Martin Fuchs, Helmut Friess, Stefanie Combs, Barbara Häussler, Jutta Engel, Kathrin Halfter
Background It remains unclear whether radiation therapy (RT) has an impact on the development of secondary primary cancer (SC) in rectal cancer (RC) patients, especially within the true pelvis. Aim To examine the incidence of SC in a population-based cohort of RC after surgical treatment with or without radiation therapy (RT, NRT). Patients and Methods The epidemiological cohort consisting of 13,919
-
Outcomes Following Recent and Distant Neoadjuvant Radiation in Rectal Cancer: An Institutional Retrospective Review and Analysis of NSQIP Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-09-16 Kevin Arndt, Ana Sofia Ore, Jeanne Quinn, Anne Fabrizio, Kristen Crowell, Evangelos Messaris, Thomas Cataldo
Background Neoadjuvant chemoradiotherapy (nCRT) is the standard of care in locally advanced rectal cancer (LARC). However, radiation therapy is thought to increase operative difficulty due to induction of fibrosis. Total neoadjuvant therapy (TNT) protocols increase the time between completion of radiation and surgical resection which may lead to increased operative difficulty and complications. Methods
-
Stereotactic Body Radiotherapy for Management of Pulmonary Oligometastases in Stage IV Colorectal Cancer: A Perspective Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-09-09 Michael X. Fu, Catarina Carvalho, Bella Milan-Chhatrisha, Nishita Gadi
In pulmonary oligometastases from colorectal cancer (POM-CRC), metastasectomy is the primarily recommended treatment. Stereotactic body radiotherapy (SBRT) has been suggested as a viable alternative therapy. SBRT efficacy for POM-CRC is poorly delineated compared to selected non-CRC primaries. This perspective article aims to critically summarize the existing evidence regarding efficacy of SBRT in
-
Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis: A Retrospective Cohort Study Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-08-31 Yijiao Chen, Dexiang Zhu, Miao Chen, Yuqiu Xu, Qinghai Ye, Xiaoying Wang, Pingping Xu, Qingyang Feng, Meiling Ji, Ye Wei, Jia Fan, Jianmin Xu
Background For patients with initially unresectable colorectal liver metastasis (IU-CRLM) receiving conversion therapy, disease relapse after conversion hepatectomy is common. However, few studies have focused on the assessment and management of relapse following conversion hepatectomy for IU-CRLM. Methods In the retrospective cohort study, 255 patients with IU-CRLM received conversion therapy and
-
-
-
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-08-23 Di Maria Jiang, Shruti Parshad, Luna Zhan, Hao-Wen Sim, Lillian L. Siu, Geoffrey Liu, Jeremy D. Shapiro, Timothy J. Price, Derek J. Jonker, Christos S. Karapetis, Andrew H. Strickland, Wenjiang Zhang, Mark Jeffery, Dongsheng Tu, Siobhan Ng, Sabe Sabesan, Jenny Shannon, Amanda Townsend, Chris J. O'Callaghan, Eric X. Chen
Background Cetuximab is a standard of care therapy for patients with RAS wild-type (WT) advanced colorectal cancer. Limited data suggest a wide variation in cetuximab plasma concentrations after standard dosing regimens. We correlated cetuximab plasma concentrations with survival and toxicity. Methods The CO. 20 study randomized patients with RAS WT advanced colorectal cancer in a 1:1 ratio to cetuximab
-
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-08-11 Filippo Ghelardi, Alessandra Raimondi, Federica Morano, Giovanni Randon, Alessandra Pannone, Marcello Guaglio, Giacomo Mazzoli, Vincenzo Nasca, Massimo Milione, Giuseppe Leoncini, Giovanna Sabella, Gabriella Francesca Greco, Bianca Rosa Lampis, Margherita Galassi, Sara Delfanti, Margherita Nannini, Rossana Intini, Dario Baratti, Maria Di Bartolomeo, Marcello Deraco, Filippo Pietrantonio
Introduction Pseudomyxoma peritonei (PMP) is a rare, slow growing tumor, traditionally considered chemoresistant. The only curative approach is cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC). At disease relapse, or in patients with inoperable disease at diagnosis, no standard treatment has been defined, though nonrandomized series showed promising results
-
Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-08-09 Ofer Margalit, Sivan Lieberman, Ilanit Redinsky, Sharon Halparin, Nir Honig, Stephen Raskin, Maoz Ben-Ayun, Einat Shacham-Shmueli, Naama Halpern, Damien Urban, Aliza Ackerstein, Katerina Shulman, Eytan Ben-Ami, Valeriya Semenisty, Ofer Purim, Nirit Yarom, Talia Golan, Ben Boursi, Sarit Appel, Zvi Symon, Yaacov R. Lawrence
Introduction Microsatellite stable metastatic colorectal cancer (MSS mCRC) is largely refractory to immune checkpoint inhibition. We hypothesized that a combination of intratumoral TLR9 agonist, radiosurgery and dual PD-1 and CTLA-4 blockade would induce a local focus of immune stimulation, evoking a systemic immune response. Patients and Methods In this phase I single-institution study, patients with
-
Trends and Prescriber Variation in the Duration of Oxaliplatin-Containing Adjuvant Chemotherapy for Stage III Colon Cancer From 2007 to 2019: A Population-Based Retrospective Cohort Study Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-08-07 Colin Sue-Chue-Lam, Christine Brezden-Masley, Rinku Sutradhar, Amy Y.X. Yu, Nancy N. Baxter
Introduction The International Duration Evaluation of Adjuvant Therapy (IDEA) collaboration in 2017 established 3 months of adjuvant therapy as an alternative to 6 months of therapy for stage III colon cancer. We determined the association between the IDEA publication, changes in clinical practice, and prescriber variation. Patients and Methods Using linked databases, we identified Ontarians aged ≥18
-
Survivorship in Early-Stage Rectal Cancer Patients Who Have Received Combined Modality Therapy Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-08-06 Saboor E. Randhawa, Laura Tenner
Survival rates in early-stage rectal cancer patients have increased over the past few decades. Societies such as the National Comprehensive Cancer Network (NCCN), American Cancer Society (ACS), American Society of Clinical Oncology (ASCO), and European Society of Medical Oncology (ESMO) have proposed guidelines related to cancer survivorship care including formal recommendations to address the needs
-
The Importance of Feasibility Assessment in the Design of ctDNA Guided Trials – Results From the OPTIPAL II Study Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-08-06 Louise Bach Callesen, Anders Kindberg Boysen, Christina Søs Auður Andersen, Niels Pallisgaard, Karen-Lise Garm Spindler
Introduction Both quantitative and molecular changes in ctDNA can hold important information when treating metastatic colorectal cancer (mCRC), but its clinical utility is yet to be established. Before conducting a large-scale randomized trial, it is essential to test feasibility. This study investigates whether ctDNA is feasible for detecting patients who will benefit from treatment with epidermal
-
Anxiety is Associated With Geriatric Assessment Impairments and Reduced Quality of Life Among Older Adults With Colorectal Cancer: Results From the CARE Registry Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-08-05 Daniel L. Hess, Mackenzie E. Fowler, Christian Harmon, Smith Giri, Grant R. Williams
Background Colorectal cancer (CRC) preferentially affects older adults. Modifiable factors, such as anxiety, can be measured as part of cancer-specific geriatric assessments (GA) completed prior to the start of treatment. We hypothesized that anxiety is prevalent among older adults with CRC and is associated with increased depression, increased frailty, and impaired health-related quality of life (HRQOL)
-
Colon Cancer Survivorship in Patients Who Have Received Adjuvant Chemotherapy Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-07-28 Meghana Kesireddy, Laura Tenner
The number of colon cancer survivors in the United States is increasing due to improved early detection, better treatments that extend survival, and the growing aging population who are at high risk for cancer. Following initial active treatment, colon cancer survivors experience a wide range of long-term physical, psychological, and socio-economic effects that impact their overall well-being. Healthcare
-
Intratumoral Budding and CD8-Positive T-cell Density in Pretreatment Biopsies as a Predictor of Response to Neoadjuvant Chemoradiotherapy in Advanced Rectal Cancer Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-07-22 Shuhei Sano, Takashi Akiyoshi, Noriko Yamamoto, Yukiharu Hiyoshi, Toshiki Mukai, Tomohiro Yamaguchi, Toshiya Nagasaki, Akinobu Taketomi, Yosuke Fukunaga, Hiroshi Kawachi
Background Neoadjuvant chemoradiotherapy (CRT) is the standard treatment for advanced rectal cancer. Yet, the response to CRT varies from complete response to zero tumor regression. Materials and Methods The impact of intratumoral budding (ITB) and intratumoral CD8+ cell density on response to CRT and survival were evaluated in biopsy samples from 266 patients with advanced rectal cancer who were treated
-
How Patients Cope Throughout the Course of an Incurable Cancer Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-07-10 Ariana Bauer, Melissa Teply
Patients cope in different ways when living with an incurable cancer. These varied coping styles impact how oncology providers communicate with patients. If providers do not tailor communication with a general understanding of how a patient is coping, this risks miscommunication with the patient, inaccurate disease understanding, and suboptimal care. This review explores the spectrum of coping patterns
-
The Next Best Thing: Three Key Conversations to Convey Prognosis Over the Course of an Incurable Cancer Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-07-10 Lindsay Gage, Melissa Teply
Introduction Waiting until a person is very near end of life to discuss limited life expectancy risks lower goal-concordant care and increased utilization of medical interventions with lower likelihood of benefit at the end of life. Medical training on communication skills in serious illness often focuses on early and late conversations regarding prognosis, with no guidance on navigating the conversations
-
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-06-11 Beatrice Borelli, Veronica Conca, Martina Carullo, Aldo Sainato, Roberto Mattioni, Bruno Manfredi, Riccardo Balestri, Piero Buccianti, Luca Morelli, Piercarlo Rossi, Paola Vagli, Alessandra Anna Prete, Frassineti Luca, Federica Morano, Samantha Di Donato, Lisa Salvatore, Carmelo Bengala, Daniele Rossini, Luca Boni, Carlotta Antoniotti, Roberto Moretto
Background In patients with locally advanced rectal cancer (LARC) treated with preoperative (chemo) radiotherapy and surgery, adjuvant chemotherapy is poorly feasible and its benefit is questionable. In the last years, several total neoadjuvant treatment (TNT) strategies, moving the adjuvant chemotherapy to the neoadjuvant setting, have been investigated with the aim of improving compliance to systemic
-
TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-06-07 Shonosuke Wakayama, Kota Ouchi, Shin Takahashi, Yasuhide Yamada, Yoshito Komatsu, Ken Shimada, Tatsuro Yamaguchi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka
Background Neither TP53 mutation nor DNA methylation status has been established as a biomarker alone of metastatic colorectal cancer. We analyzed the association between TP53 mutation functional subtypes and genome-wide DNA methylation status (GWMS) as combined prognostic markers. Methods Patient clinical data were obtained from the TRICOLORE study, a randomized phase III trial. The TP53 mutations
-
-
-
Revisiting the Radical Radiotherapy-Radiochemotherapy Results in Anal Canal Cancers: (TROD Gastrointestinal Group Study 02-005) Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-05-22 Sule Karabulut GUL, Huseyin Tepetam, Ferah Yildiz, Ilhami Er, Didem Colpan Oksuz, Murtaza Parvizi, Ayse Sevgi Ozden, Zumre Arican Alicikus, Sezin Yuce Sari, Omar Alomari, Ilknur Bilkay Gorken
Background and Aim This study aimed to determine treatment outcomes and factors affecting prognosis in patients diagnosed with anal canal cancer who received radical radiotherapy (RT) or radiotherapy combined with chemotherapy (CT-RT) in radiation oncology centers in Turkey and compare the results with literature. Material and Method The study included 193 patients with anal canal cancer reported between
-
Preoperative Radiotherapy Decision-Tree for Rectal Cancer Patients: A Real-World Analysis Based on the Swedish Colorectal Cancer Registry Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-05-14 Bin Luo, Chuanwen Fan, Xuqin Xie, Per Loftås, Xiao-Feng Sun
-
Effect of High-Versus Low-Frequency of Abdominopelvic Computed Tomography Follow-Up Testing on Overall Survival in Patients With Stage II Or III Colon Cancer Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-05-11 Jeongseok Jeon, Da Bin Lee, Sang Joon Shin, Dai Hoon Han, Jee Suk Chang, Yoon Dae Han, Hyunwook Kim, Joon Seok Lim, Han Sang Kim, Joong Bae Ahn
Background Intensive surveillance of colon cancer by using the abdominopelvic computed tomography (AP-CT) is common in real world practice; however, it is still unclear whether high-frequency surveillance using AP-CT in patients with these risk factors is superior to that in the low-frequency surveillance. Patients and Methods We retrospectively reviewed 1803 patients with stage II-III colon cancer
-
Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-05-11 Hiroyuki Kodama, Toshiki Masuishi, Munehiro Wakabayashi, Akinobu Nakata, Ryosuke Kumanishi, Taiko Nakazawa, Takatsugu Ogata, Yuki Matsubara, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Kei Muro
Background The recommended first-line chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer (mCRC) is bevacizumab (BEV)-containing therapy for right-sided colon cancer (R) and antiepidermal growth factor receptor antibody (anti-EGFR)-containing therapy for left-sided colon cancer (L) or rectal cancer (RE). However, anatomical or biological heterogeneity reportedly exists between L and RE
-
Effects of Palliative Chemotherapy in Unresectable or Metastatic Colorectal Cancer Patients With Poor Performance Status Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-05-11 Lucila Soares da Silva Rocha, Camila Motta Venchiarutti Moniz, Marilia Polo Mingueti e Silva, Guilherme Fialho de Freitas, Virgilio Souza e Silva, Paulo Marcelo Gehm Hoff, Rachel P. Riechelmann
Introduction Colorectal cancer is the second most common cancer in both genders and often presents as a metastatic, unresectable, or recurrent disease in early follow-up. It is uncertain the benefit of oxaliplatin-based palliative chemotherapy (CT) in the first line of treatment in patients with compromised performance status (PS), Eastern Cooperative Oncology Group (ECOG) 3 and 4. These patients are
-
Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-03-28 Chih-Wen Chen, Tao-Shen Ou, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Yi-Wen Yang, Yu-Zu Lin, Yee Chao, Ling-Wei Wang, Hao-Wei Teng
Background Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM. Methods A total of 65 patients with CBM under treatment were retrospectively enrolled
-
Intensification of Local Therapy With High Dose Rate, Intraoperative Radiation Therapy (HDR-IORT) and Extended Resection for Locally Advanced and Recurrent Colorectal Cancer Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-03-26 Ryan Anthony F. Agas, Jennifer Tan, Jing Xie, Sylvia Van Dyk, Joseph C.H. Kong, Alexander Heriot, Samuel Y. Ngan
Background We report our long-term experience with high dose rate intraoperative radiotherapy (HDR-IORT) in a single, quaternary institution. Patients/Methods From 2004 to 2020, 60 HDR-IORT procedures for locally advanced colorectal cancer (LACC) and 81 for locally recurrent colorectal cancer (LRCC) were done in our institution. Preoperative radiotherapy was done prior to majority of the resections
-
-
-
The Role of Immunotherapy in Esophageal and Gastric Cancer Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-03-15 Hans Dedecker, Laure-Anne Teuwen, Timon Vandamme, Andreas Domen, Hans Prenen
Upper gastrointestinal tract tumors historically have a poor prognosis. The decision to treat esophageal or gastric cancers by surgery, radiotherapy, systemic therapy, or a combination of these treatment modalities should always be discussed multidisciplinary. The introduction of immunotherapy has drastically transformed the treatment landscape of multiple solid malignancies. Emerging data from early
-
Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role? Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-03-04 Joseph Sgouros, Stefania Gkoura, Nikolaos Spathas, Fotios Tzoudas, Konstantinos Karampinos, Nikolaos Miaris, Anastasios Visvikis, Nick Dessypris, Davide Mauri, Gerasimos Aravantinos, Ilias Theodoropoulos, George Stamoulis, Epaminondas Samantas
Introduction/Background Adjuvant capecitabine monotherapy is an option for colon and upper rectum adenocarcinoma patients, providing they have stage II disease with an intermediate risk of recurrence, or stage III but they are above 70’s or they have comorbidities. We wanted to examine whether the number of chemotherapy cycles and the relative dose intensity (RDI) of capecitabine monotherapy in the
-
A Case of Heavily Pretreated HER2+ Colorectal Liver Metastases Responsive to Hepatic Arterial Infusion Chemotherapy Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-02-24 Ryan J. Beechinor, Mustafa F. Abidalhassan, Deborah F. Small, Huong K. Hoang, Ramit Lamba, Thomas W Loehfelm, Cameron C. Foster, Michael Z. Koontz, Edward Jae-Hoon Kim, May Cho, Sepideh Gholami
What is Already Known About This Subject?Hepatic arterial infusion (HAI) pumps represent 1 promising treatment strategy for patients presenting with liver only or predominant tumors. HAI therapy is a form of locoregional therapy which administers chemotherapy directly into the hepatic artery, thus limits systemic exposure and spares other organs from toxicity. According to the National Comprehensive
-
SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS) Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-02-22 Mark P. Saunders, Rohan Iype, Caroline Kelly, Jana Crosby, Rachel Kerr, Andrea Harkin, Karen Allan, John McQueen, Sarah R Pearson, James Cassidy, Louise C. Medley, Sherif Raouf, Mark Harrison, Alison Brewster, Charlotte Rees, Richard Ellis, Anne L. Thomas, Mark Churn, Timothy Iveson, Noori Maka
Aim Patients with loco-regional right-sided colorectal tumors have a worse overall survival (OS). Here we investigate the difference in disease free survival (DFS) between colorectal patients with right and left sided tumors in the SCOT study. Methods The SCOT study showed 3-months of oxaliplatin-containing adjuvant chemotherapy (OxFp) is non-inferior to 6-months for patients with stage III and high-risk
-
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-02-21 P. Jiménez-Fonseca, J. Sastre, P. García-Alfonso, M.A. Gómez-España, A. Salud, S. Gil, F. Rivera, J.J. Reina, G. Quintero, M. Valladares-Ayerbes, M.J. Safont, A. La Casta, L. Robles-Díaz, B. García-Paredes, R. López López, M. Guillot, J. Gallego, V. Alonso-Orduña, E. Diaz-Rubio, E. Aranda
Background The bCTC count is a well-established prognostic biomarker in mCRC, as well as in other tumor types. The aim of this analysis was to evaluate the prognostic/predictive role of the bCTC count (≥3 vs. <3) in previously untreated mCRC. Patients and Methods The study involved 589 untreated mCRC patients included in the intention-to-treat population of 2 randomized clinical trials (phase III VISNU-1
-
Optimizing Screening for Colorectal Cancer: An Algorithm Combining Fecal Immunochemical Test, Blood-Based Cancer-Associated Proteins and Demographics to Reduce Colonoscopy Burden Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-02-15 Mathias M. Petersen, Jakob Kleif, Lars N. Jørgensen, Jakob W. Hendel, Jakob B. Seidelin, Mogens R. Madsen, Jesper Vilandt, Søren Brandsborg, Jørn S. Rasmussen, Lars M. Andersen, Ali Khalid, Linnea Ferm, Susan H. Gawel, Frans Martens, Berit Andersen, Morten Rasmussen, Gerard J. Davis, Ib J. Christensen, Christina Therkildsen
Background Fecal Immunochemical Test (FIT) is widely used in population-based screening for colorectal cancer (CRC). This had led to major challenges regarding colonoscopy capacity. Methods to maintain high sensitivity without compromising the colonoscopy capacity are needed. This study investigates an algorithm that combines FIT result, blood-based biomarkers associated with CRC, and individual demographics
-
Patient-reported Bowel Function and Bowel-related Quality of Life After Pelvic Radiation for Rectal Adenocarcinoma: The Impact of Radiation Fractionation and Surgical Resection Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-02-15 Michael K. Rooney, Brian De, Kelsey Corrigan, Grace L. Smith, Cullen Taniguchi, Bruce D. Minsky, Ethan B. Ludmir, Eugene J. Koay, Prajnan Das, Albert C. Koong, Oliver Peacock, George Chang, Y. Nancy You, Van K. Morris, Graciela Nogueras-González, Emma B. Holliday
Introduction Multimodality treatment for locally advanced rectal cancer (LARC) can include long-course radiotherapy (LCRT) or short course radiotherapy (SCRT). Nonoperative management is increasingly pursued for those achieving a complete clinical response. Data regarding long-term function and quality-of-life (QOL) are limited. Methods Patients with LARC treated with radiotherapy from 2016 to 2020
-
Cancers of the Pancreas Update 2023 Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-02-13 Jordan Berlin
Abstract not available
-
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial Clin. Colorectal Cancer (IF 3.4) Pub Date : 2023-02-05 Debora Basile, Gerardo Rosati, Francesca Bergamo, Silvio Ken Garattini, Maria Banzi, Maria Zampino, Silvia Bozzarelli, Paolo Marchetti, Fabio Galli, Francesca Galli, Raffaella Longarini, Alberto Zaniboni, Daris Ferrari, Sabino De Placido, Luca Giovanni Frassineti, Mario Nicolini, Saverio Cinieri, Michele Priscindiaro, Pina Ziranu, Riccardo Caccialanza, Giuseppe Aprile
Background High body mass index (BMI) plays a key role in the development of colon cancer (CC). Our post-hoc analysis from the TOSCA trial analyzed the association between BMI and survival outcomes in terms of relapse-free survival (RFS) and overall survival (OS) in stage II/III CC patients. Patients and methods Patients enrolled in the TOSCA trial between 2007-2013 with BMI data entered the study